Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 19;22(1):2.
doi: 10.1007/s11897-024-00689-3.

Ceramides as Biomarkers of Cardiovascular Diseases and Heart Failure

Silvio N Augusto Jr  1 , Abhilash Suresh  2 , W H Wilson Tang  3   4   5
Affiliations
Review

Ceramides as Biomarkers of Cardiovascular Diseases and Heart Failure

Silvio N Augusto Jr et al. Curr Heart Fail Rep. .

Abstract

Purpose of review: Ceramides are lipid species that play several physiological roles in the body, including stress response, inflammation, and apoptosis, and their involvement in lipid metabolism and energy production makes them crucial in the pathophysiology of heart failure (HF).

Recent findings: Several species of ceramides and ceramide signatures have recently been investigated as possible biomarkers of cardiovascular disease (CVD), and risk scores have demonstrated prognostic value in stratifying patients by risk and possibly predicting adverse cardiac events. With growing interest in targeting metabolic dysfunction, understanding the role of ceramides in CVD also opens the possibility of novel therapeutics that target ceramide metabolism to improve cardiac function and cardiac outcomes in patients. Understanding the role of ceramides in CVD opens the possibility of novel diagnostics and theragnostic targeting ceramide metabolism to improve cardiac function and cardiac outcomes in patients with heart failure.

Keywords: Cardiovascular diseases; Ceramides; Heart failure; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing Interests Dr. Tang has served as consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, WhiteSwell, Boston Scientific, CardiaTec Biosciences, Bristol Myers Squibb, Alleviant Medical, Alexion Pharmaceuticals, Salubris Biotherapeutics, BioCardia, and has received honorarium from Springer, Belvoir Media Group, and American Board of Internal Medicine. All other authors have no relationships to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87. https://doi.org/10.1093/cvr/cvac013 . - DOI - PubMed
    1. Roger VL. Epidemiology of Heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–34. https://doi.org/10.1161/circresaha.121.318172 . - DOI - PubMed
    1. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–50. https://doi.org/10.1038/nrm2329 . - DOI - PubMed
    1. Cantalupo A, Sasset L, Gargiulo A, Rubinelli L, Del Gaudio I, Benvenuto D, et al. Endothelial sphingolipid De Novo Synthesis controls Blood pressure by regulating Signal Transduction and NO via Ceramide. Hypertension. 2020;75(5):1279–88. https://doi.org/10.1161/hypertensionaha.119.14507 . - DOI - PubMed
    1. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014;510(7503):58–67. https://doi.org/10.1038/nature13475 . - DOI - PubMed - PMC

LinkOut - more resources